Derek Lowe is terrific in communicating complex ideas in the field to concerned lay observers like me; he's been a great resource for reliable information about the science of this thing.
Just to clarify; the ChAdOx1 MERS prospect hasn't proceeded to a trial demonstrating efficacy in human subjects (as yet).
That's a particularly important distinction here, given the nature of the novel delivery mechanism[1] and prior observation of complications in SARS-CoV-1 vaccine development[2]